Inactive

This synopsis is hereby issued in accordance with FAR Part 5.203 and FAR 6.302-3(a)(2)(ii) in response to the mandatory requirement for a 15 day notification. The purpose of this synopsis is to announ... This synopsis is hereby issued in accordance with FAR Part 5.203 and FAR 6.302-3(a)(2)(ii) in response to the mandatory requirement for a 15 day notification. The purpose of this synopsis is to announce the Food and Drug Administration's intent to negotiate a Firm Fixed Price sole source modification to an existing contract with the University of Louisville located at 2301 S 3rd St Louisville, KY, 40208-1838. The current contract number is HHSF223201810171C, entitled “Development of a Mouse Model for Preclinical Screening of Investigational Drugs Against Pseudomonas Aeruginosa and Acinetobacter Baumannii.” The Fixed Price modification is necessary to expand the scope of the study resulting in more statistically significant results and ensure accuracy regarding strains of interest to the FDA when combined with the results of the initial results of the first execution. This action will provide for more meaningful and comprehensive data in a timely manner without substantial duplication of cost and effort and/or risk to performance. Therefore, in accordance with the authority of FAR 6.302-3(a)(2)(ii) and the application of FAR 6.302-3(b)(2)(i), it is necessary to award this modification to the University of Louisville in order to maintain an essential research capability to be provided by an educational institution and to maintain an essential capability for theoretical analyses, exploratory studies, or experiments in any field of science or technology.” The anticipated extension to the period of performance for this modification is seven (7) months following execution of the modification. The estimated total amount of this modification is approximately $173,128.33. THIS NOTICE IS NOT A REQUEST FOR COMPETITIVE PROPOSALS, however, interested firms may submit a capability statement in response to the above requirement with pricing information by March 26, 2020 @ 5:30 PM Local Time to Nikola Zuber, Contract Specialist, Phone: (301) 796-9671, Email: Nikola.Zuber@fda.hhs.gov.